Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $48,943.11 in Stock

Major shareholder Ansbert Gadicke sold 52,627 shares of Werewolf Therapeutics at $0.93 per share, totaling $48,943.11. This sale decreased his ownership by 0.96%. The transaction was disclosed to the SEC. Gadicke has made several other sales recently, impacting the stock's performance. Werewolf Therapeutics' stock is currently trading at $0.81, with a market cap of $39.37 million.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) major shareholder Ansbert Gadicke sold 52,627 shares of the firm's stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $0.93, for a total value of $48,943.11. Following the completion of the sale, the insider owned 5,428,912 shares in the company, valued at approximately $5,048,888.16. This represents a 0.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Ansbert Gadicke also recently made the following trade(s):

On Thursday, November 20th, Ansbert Gadicke sold 41,152 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $36,625.28.
On Wednesday, November 19th, Ansbert Gadicke sold 66,324 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total value of $62,344.56.
On Monday, November 17th, Ansbert Gadicke sold 57,061 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.95, for a total value of $54,207.95.
On Friday, November 14th, Ansbert Gadicke sold 61,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total transaction of $57,325.20.
On Thursday, November 13th, Ansbert Gadicke sold 90,951 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total transaction of $89,131.98.
On Wednesday, November 12th, Ansbert Gadicke sold 40,669 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.09, for a total transaction of $44,329.21.
On Tuesday, November 11th, Ansbert Gadicke sold 55,810 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total transaction of $63,623.40.
On Monday, November 10th, Ansbert Gadicke sold 48,570 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.18, for a total transaction of $57,312.60.
On Friday, November 7th, Ansbert Gadicke sold 68,480 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.11, for a total transaction of $76,012.80.
On Thursday, November 6th, Ansbert Gadicke sold 54,452 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total value of $65,886.92.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock traded down $0.04 on Friday, hitting $0.81. The stock had a trading volume of 563,187 shares, compared to its average volume of 502,613. The stock has a market cap of $39.37 million, a price-to-earnings ratio of -0.50 and a beta of 0.72. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 52-week low of $0.60 and a 52-week high of $2.38. The company's 50 day moving average price is $1.54 and its 200 day moving average price is $1.33.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.03. On average, research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of large investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. lifted its stake in shares of Werewolf Therapeutics by 33.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company's stock valued at $93,000 after purchasing an additional 23,852 shares during the period. Nuveen LLC purchased a new position in Werewolf Therapeutics in the first quarter valued at about $71,000. MPM Asset Management LLC lifted its position in shares of Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company's stock valued at $4,189,000 after acquiring an additional 25,688 shares during the period. MPM Bioimpact LLC boosted its stake in shares of Werewolf Therapeutics by 0.9% during the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company's stock worth $2,341,000 after acquiring an additional 20,799 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new stake in shares of Werewolf Therapeutics in the 1st quarter worth approximately $79,000. Hedge funds and other institutional investors own 64.84% of the company's stock.

Analyst Ratings Changes

HOWL has been the topic of a number of recent research reports. Zacks Research upgraded shares of Werewolf Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Thursday, October 16th. JMP Securities dropped their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 21st. Bank of America decreased their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a "buy" rating for the company in a research report on Tuesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Finally, Citigroup restated a "market outperform" rating on shares of Werewolf Therapeutics in a research note on Wednesday, November 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $7.75.

Check Out Our Latest Report on HOWL

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.